Sources: - Lilly's next-gen drug tops Zepbound on weight loss in late-stage osteoarthritis trial (Published: 2025-12-11) - - American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease - 2025 Update - PubMed (Published: 2025-01-01) - - Introduction and methodology: Standards of Care in Overweight and Obesity2025 | BMJ Open Diabetes Research & Care (Published: 2025-05-23) - #ObesityMedicine #WeightLoss #Retatrutide #TripleAgonist #GLP1 #ChronicDisease #HealthcareInnovation #Pharma #CardiovascularHealth #ObesityTreatment To view or add a comment, sign in Obesity, Metabolic Syndrome, and Osteoarthritis Require Integrative Understanding and Management by Mocanu, V., et al
Furthermore, in jurisdictions where certain probiotics are regulated as prescription medications, consultation with a physician or a clinically trained pharmacist is imperative (517)
Can genetic testing help me choose between semaglutide and tirzepatide if I'm on blood thinners
In some medical malpractice cases, doctors fail to order an MRI or CT scan, leading to a delayed diagnosis
1 Introduction Parkinsons disease (PD) is one of the most disabling diseases globally ( Type 2 diabetes mellitus (T2DM) is considered one of the risk factors for PD ( 2 Dopaminergic neurotransmission in PD pathogenesis The dopaminergic neurotransmission in PD pathogenesis involves the loss and apoptosis of dopaminergic neurons in the brain, as well as a reduction in dopamine levels, leading to an absolute deficiency of dopamine ( 3 PD pathogenesis and glucose metabolism and energy conversion disorders The pathogenesis of PD is linked to disturbances in glucose metabolism and energy conversion disorders
